Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Spreafico

Showing results (1-10 of 186) with videos related to

Pageof 19
Sort By:
Expert Opinion on Investigational Drugs|August 23, 2013
Current phase II clinical data for ridaforolimus in cancerAnna Spreafico, Helen J Mackay
British Journal of Cancer|July 22, 2020
Increasing operational and scientific efficiency in clinical trialsDeirdre Kelly, Anna Spreafico, Lillian L Siu
Cells|January 11, 2024
Promising and Minimally Invasive Biomarkers: Targeting MelanomaPavlina Spiliopoulou, Carlos Diego Holanda Lopes, Anna Spreafico
International Journal of Molecular Sciences|January 21, 2023
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous CancersPavlina Spiliopoulou, Olga Vornicova, Sofia Genta, et al.
Cells|December 17, 2024
Extracellular Vesicles and Their Applications in Tumor Diagnostics and ImmunotherapyScott Strum, Valentina Evdokimova, Laszlo Radvanyi, et al.
Frontiers in Oncology|August 29, 2022
Patient-derived cancer models: Valuable platforms for anticancer drug testingSofia Genta, Bryan Coburn, David W Cescon, et al.
Molecular Cancer Therapeutics|June 18, 2020
Patient Selection Strategies to Maximize Therapeutic Index of Antibody-Drug Conjugates: Prior Approaches and Future DirectionsMarna Williams, Anna Spreafico, Kapil Vashisht, et al.
Current Treatment Options in Oncology|May 31, 2017
The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?Lindsay Carlsson, Scott V Bratman, Lillian L Siu, et al.
British Journal of Clinical Pharmacology|May 13, 2020
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature reviewFred R Hirsch, Anna Spreafico, Silvia Novello, et al.
Pageof 19

Showing results (1-10 of 186) with videos related to

Sort By:
Pageof 19
Expert Opinion on Investigational Drugs|August 23, 2013
Current phase II clinical data for ridaforolimus in cancerAnna Spreafico, Helen J Mackay
British Journal of Cancer|July 22, 2020
Increasing operational and scientific efficiency in clinical trialsDeirdre Kelly, Anna Spreafico, Lillian L Siu
Cells|January 11, 2024
Promising and Minimally Invasive Biomarkers: Targeting MelanomaPavlina Spiliopoulou, Carlos Diego Holanda Lopes, Anna Spreafico
International Journal of Molecular Sciences|January 21, 2023
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous CancersPavlina Spiliopoulou, Olga Vornicova, Sofia Genta, et al.
Cells|December 17, 2024
Extracellular Vesicles and Their Applications in Tumor Diagnostics and ImmunotherapyScott Strum, Valentina Evdokimova, Laszlo Radvanyi, et al.
Frontiers in Oncology|August 29, 2022
Patient-derived cancer models: Valuable platforms for anticancer drug testingSofia Genta, Bryan Coburn, David W Cescon, et al.
Molecular Cancer Therapeutics|June 18, 2020
Patient Selection Strategies to Maximize Therapeutic Index of Antibody-Drug Conjugates: Prior Approaches and Future DirectionsMarna Williams, Anna Spreafico, Kapil Vashisht, et al.
Current Treatment Options in Oncology|May 31, 2017
The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?Lindsay Carlsson, Scott V Bratman, Lillian L Siu, et al.
British Journal of Clinical Pharmacology|May 13, 2020
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?Geoffrey Alan Watson, Jeffrey Doi, Aaron Richard Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 6, 2008
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature reviewFred R Hirsch, Anna Spreafico, Silvia Novello, et al.
Pageof 19